105 related articles for article (PubMed ID: 16982079)
1. Release of cellular proteases into the acidic extracellular milieu exacerbates Ebola virus-induced cell damage.
Barrientos LG; Rollin PE
Virology; 2007 Feb; 358(1):1-9. PubMed ID: 16982079
[TBL] [Abstract][Full Text] [Related]
2. Ebola virus defective interfering particles and persistent infection.
Calain P; Monroe MC; Nichol ST
Virology; 1999 Sep; 262(1):114-28. PubMed ID: 10489346
[TBL] [Abstract][Full Text] [Related]
3. Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection.
Chandran K; Sullivan NJ; Felbor U; Whelan SP; Cunningham JM
Science; 2005 Jun; 308(5728):1643-5. PubMed ID: 15831716
[TBL] [Abstract][Full Text] [Related]
4. Ebola virus: the role of macrophages and dendritic cells in the pathogenesis of Ebola hemorrhagic fever.
Bray M; Geisbert TW
Int J Biochem Cell Biol; 2005 Aug; 37(8):1560-6. PubMed ID: 15896665
[TBL] [Abstract][Full Text] [Related]
5. Ebola virus glycoprotein toxicity is mediated by a dynamin-dependent protein-trafficking pathway.
Sullivan NJ; Peterson M; Yang ZY; Kong WP; Duckers H; Nabel E; Nabel GJ
J Virol; 2005 Jan; 79(1):547-53. PubMed ID: 15596847
[TBL] [Abstract][Full Text] [Related]
6. Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity.
Volchkov VE; Volchkova VA; Muhlberger E; Kolesnikova LV; Weik M; Dolnik O; Klenk HD
Science; 2001 Mar; 291(5510):1965-9. PubMed ID: 11239157
[TBL] [Abstract][Full Text] [Related]
7. Antiviral drug therapy of filovirus infections: S-adenosylhomocysteine hydrolase inhibitors inhibit Ebola virus in vitro and in a lethal mouse model.
Huggins J; Zhang ZX; Bray M
J Infect Dis; 1999 Feb; 179 Suppl 1():S240-7. PubMed ID: 9988190
[TBL] [Abstract][Full Text] [Related]
8. Generation of eGFP expressing recombinant Zaire ebolavirus for analysis of early pathogenesis events and high-throughput antiviral drug screening.
Towner JS; Paragas J; Dover JE; Gupta M; Goldsmith CS; Huggins JW; Nichol ST
Virology; 2005 Feb; 332(1):20-7. PubMed ID: 15661137
[TBL] [Abstract][Full Text] [Related]
9. Analysis of filovirus entry into vero e6 cells, using inhibitors of endocytosis, endosomal acidification, structural integrity, and cathepsin (B and L) activity.
Sanchez A
J Infect Dis; 2007 Nov; 196 Suppl 2():S251-8. PubMed ID: 17940957
[TBL] [Abstract][Full Text] [Related]
10. Proteolysis of the Ebola virus glycoproteins enhances virus binding and infectivity.
Kaletsky RL; Simmons G; Bates P
J Virol; 2007 Dec; 81(24):13378-84. PubMed ID: 17928356
[TBL] [Abstract][Full Text] [Related]
11. A reconstituted replication and transcription system for Ebola virus Reston and comparison with Ebola virus Zaire.
Boehmann Y; Enterlein S; Randolf A; Mühlberger E
Virology; 2005 Feb; 332(1):406-17. PubMed ID: 15661171
[TBL] [Abstract][Full Text] [Related]
12. rd1 Mouse retina shows an imbalance in the activity of cysteine protease cathepsins and their endogenous inhibitor cystatin C.
Ahuja S; Ahuja-Jensen P; Johnson LE; Caffé AR; Abrahamson M; Ekström PA; van Veen T
Invest Ophthalmol Vis Sci; 2008 Mar; 49(3):1089-96. PubMed ID: 18326735
[TBL] [Abstract][Full Text] [Related]
13. An analysis of features of pathogenesis in two animal models of Ebola virus infection.
Ryabchikova EI; Kolesnikova LV; Luchko SV
J Infect Dis; 1999 Feb; 179 Suppl 1():S199-202. PubMed ID: 9988185
[TBL] [Abstract][Full Text] [Related]
14. Protective efficacy of neutralizing antibodies against Ebola virus infection.
Takada A; Ebihara H; Jones S; Feldmann H; Kawaoka Y
Vaccine; 2007 Jan; 25(6):993-9. PubMed ID: 17055127
[TBL] [Abstract][Full Text] [Related]
15. Role of endosomal cathepsins in entry mediated by the Ebola virus glycoprotein.
Schornberg K; Matsuyama S; Kabsch K; Delos S; Bouton A; White J
J Virol; 2006 Apr; 80(8):4174-8. PubMed ID: 16571833
[TBL] [Abstract][Full Text] [Related]
16. Rapid and simple detection of Ebola virus by reverse transcription-loop-mediated isothermal amplification.
Kurosaki Y; Takada A; Ebihara H; Grolla A; Kamo N; Feldmann H; Kawaoka Y; Yasuda J
J Virol Methods; 2007 Apr; 141(1):78-83. PubMed ID: 17194485
[TBL] [Abstract][Full Text] [Related]
17. Analysis of Ebola virus and VLP release using an immunocapture assay.
Kallstrom G; Warfield KL; Swenson DL; Mort S; Panchal RG; Ruthel G; Bavari S; Aman MJ
J Virol Methods; 2005 Jul; 127(1):1-9. PubMed ID: 15893559
[TBL] [Abstract][Full Text] [Related]
18. Other viral bioweapons: Ebola and Marburg hemorrhagic fever.
Salvaggio MR; Baddley JW
Dermatol Clin; 2004 Jul; 22(3):291-302, vi. PubMed ID: 15207310
[TBL] [Abstract][Full Text] [Related]
19. Ebola virus: unravelling pathogenesis to combat a deadly disease.
Hoenen T; Groseth A; Falzarano D; Feldmann H
Trends Mol Med; 2006 May; 12(5):206-15. PubMed ID: 16616875
[TBL] [Abstract][Full Text] [Related]
20. Current knowledge on lower virulence of Reston Ebola virus (in French: Connaissances actuelles sur la moindre virulence du virus Ebola Reston).
Morikawa S; Saijo M; Kurane I
Comp Immunol Microbiol Infect Dis; 2007 Sep; 30(5-6):391-8. PubMed ID: 17610952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
